Trekvion® (Tablets) Instructions for Use
Marketing Authorization Holder
Obnovlenie Pfc, JSC (Russia)
ATC Code
A13A (General tonic preparations)
Active Substance
Oxyethylammonium methylphenoxy acetate (Grouping name)
Dosage Form
| Trekvion® | Tablets 200 mg |
Dosage Form, Packaging, and Composition
Tablets
| 1 tab. | |
| Oxyethylammonium methylphenoxy acetate | 200 mg |
10 pcs. – blister packs – cardboard packs (10 pcs.) – Over-the-Counter
10 pcs. – blister packs (2 pcs.) – cardboard packs (20 pcs.) – Over-the-Counter
14 pcs. – blister packs – cardboard packs (14 pcs.) – Over-the-Counter
14 pcs. – blister packs (2 pcs.) – cardboard packs (28 pcs.) – Over-the-Counter
14 pcs. – blister packs (3 pcs.) – cardboard packs (42 pcs.) – Over-the-Counter
Clinical-Pharmacological Group
Preparation with adaptogenic and restorative action
Pharmacotherapeutic Group
General tonic preparations
Pharmacological Action
An adaptogenic agent. It stimulates the production of alpha and gamma interferons and affects the immune status of the body by activating the cellular and humoral links of immunity. It stimulates the phagocytic activity of macrophages.
It strengthens the body’s immune system, increases endurance during physical and mental stress, reduces the effect of various toxins, and increases the body’s resistance to hypoxia, low and high temperatures, and other adverse environmental factors.
Pharmacokinetics
Oxyethylammonium methylphenoxy acetate has high bioavailability, is rapidly metabolized in the liver, and is excreted by the kidneys mainly in the form of glucuronides. It does not accumulate in the body with long-term use.
Indications
As part of complex therapy: for the prevention and treatment of acute respiratory viral infections; during periods of high intellectual and heavy physical exertion; to increase the body’s resistance to various stressful influences (hypoxia, overheating, hypothermia) and adverse environmental effects (sudden climate change, adaptation to changes in atmospheric pressure).
ICD codes
| ICD-10 code | Indication |
| J06.9 | Acute upper respiratory infection, unspecified |
| T67 | Effects of heat and light |
| T68 | Hypothermia |
| T70 | Effects of air pressure and water pressure |
| Z57 | Occupational exposure to risk factors |
| Z73.3 | Stress, not elsewhere classified (physical and mental strain) |
| ICD-11 code | Indication |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| NF01.Z | Exposure to heat, unspecified |
| NF02 | Hypothermia |
| NF04.Z | Exposure to atmospheric pressure and water pressure, unspecified |
| QD84.Z | Exposure to occupational risk factors, unspecified |
| QE01 | Stress, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Take Trekvion® tablets orally with water.
For the prevention and treatment of acute respiratory viral infections, take one 200 mg tablet twice daily for a duration of 10 to 14 days.
To increase resistance during periods of high intellectual or physical stress, take one 200 mg tablet once or twice daily. The duration of use is up to 30 days.
To enhance the body’s adaptation to stressful environmental factors (such as sudden climate change, hypoxia, or temperature extremes), initiate a course of one 200 mg tablet twice daily for 7 to 10 days prior to the expected exposure.
Administer the tablets in the morning and afternoon to prevent potential sleep disturbances. Do not exceed the maximum daily dose of 400 mg.
For long-term use beyond 30 days, consult a physician for evaluation and potential regimen adjustment.
The drug is contraindicated for children under 12 years of age.
Adverse Reactions
Rarely allergic reactions – hypersensitivity reactions, anaphylactic shock, anaphylaxis, angioedema.
Contraindications
Hypersensitivity to the active substance; children under 12 years of age; pregnancy, breastfeeding period.
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy and breastfeeding.
Use in Hepatic Impairment
The drug is approved for use in hepatic impairment.
Use in Renal Impairment
The drug is approved for use in renal impairment.
Pediatric Use
Contraindicated for use in children under 12 years of age (due to lack of data on efficacy and safety of use).
Geriatric Use
Approved for use in elderly patients.
Special Precautions
If, during the use of the product, pronounced symptoms of the disease persist or worsen in patients with ARVI, the product should be discontinued and a doctor should be consulted.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Mildronate capsules 500mg, 90pcs
OKI, sachets 80mg 2g, 12pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Cortexin, 10mg, 5ml, 10pcs
Phenibut-Vertex pills 250mg, 20pcs
Picamilon pills 50mg, 60pcs
Belosalic, ointment, 30g
Kagocel pills 12mg, 30pcs
Actovegin pills 200mg, 50pcs
Fenotropil pills 100mg, 60pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
No-spa pills 40mg, 64pcs
Belosalic, lotion solution for external use spray 100ml
Arbidol, capsules 100mg, 40pcs 